Literature DB >> 26660480

Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.

Y Xu1, C S Yang2, Y J Li1, X D Liu1, J N Wang1, Q Zhao1, W G Xiao1, P T Yang3.   

Abstract

Clinically amyopathic dermatomyositis (CADM) is a unique subset of dermatomyositis, showing a high incidence of lung involvements. The aim of this study is to identify risk factors, other than melanoma differentiation-associated protein (MDA)-5, for developing rapidly progressive-interstitial lung disease (RP-ILD) in patients with CADM. Forty CADM patients, in whom 11 patients developed RP-ILD, were enrolled. Clinical features and laboratory findings were compared between the patients with and without RP-ILD. We found that skin ulceration, CRP, serum ferritin, anti-MDA5 Ab, and lymphocytopenia were significantly associated with ILD. Multivariate logistic regression analysis indicated that anti-MDA5 Ab(+), elevated CRP, and decreased counts of lymphocyte were independent risk factors for RP-ILD, which can provide a precise predict for RP-ILD in CADM patients. When anti-MDA5 Ab(+) was removed from the multivariate regression model, using skin ulcerations, elevated serum ferritin and decreased counts of lymphocyte can also precisely predict RP-ILD. Except for MDA-5, more commonly available clinical characteristics, such as skin ulcerations, serum ferritin, and count of lymphocyte may also help to predict prognosis in CADM.

Entities:  

Keywords:  Amyopathic dermatomyositis; Biomarkers; Comorbidity; Rheumatic diseases

Mesh:

Substances:

Year:  2015        PMID: 26660480     DOI: 10.1007/s10067-015-3139-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  16 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?

Authors:  Richard D Sontheimer
Journal:  J Am Acad Dermatol       Date:  2002-04       Impact factor: 11.527

3.  119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

Authors:  Jessica E Hoogendijk; Anthony A Amato; Bryan R Lecky; Ernest H Choy; Ingrid E Lundberg; Michael R Rose; Jiri Vencovsky; Marianne de Visser; Richard A Hughes
Journal:  Neuromuscul Disord       Date:  2004-05       Impact factor: 4.296

4.  Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody.

Authors:  Hua Cao; Meng Pan; Yanqing Kang; Qunli Xia; Xia Li; Xiaoqing Zhao; Ruofei Shi; Jianghua Lou; Min Zhou; Masataka Kuwana; Xiaoyi Ding; Jie Zheng
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

5.  Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis.

Authors:  Takahisa Gono; Yasushi Kawaguchi; Eri Ozeki; Yuko Ota; Takashi Satoh; Masataka Kuwana; Masako Hara; Hisashi Yamanaka
Journal:  Mod Rheumatol       Date:  2010-11-05       Impact factor: 3.023

6.  Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis.

Authors:  Takahisa Gono; Yasushi Kawaguchi; Masako Hara; Ikuko Masuda; Yasuhiro Katsumata; Mikiko Shinozaki; Yuko Ota; Eri Ozeki; Hisashi Yamanaka
Journal:  Rheumatology (Oxford)       Date:  2010-04-12       Impact factor: 7.580

7.  Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis.

Authors:  Hideto Kameda; Hayato Nagasawa; Hiroe Ogawa; Naoya Sekiguchi; Hirofumi Takei; Michihide Tokuhira; Koichi Amano; Tsutomu Takeuchi
Journal:  J Rheumatol       Date:  2005-09       Impact factor: 4.666

8.  Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis.

Authors:  Shinji Sato; Michito Hirakata; Masataka Kuwana; Akira Suwa; Shinichi Inada; Tsuneyo Mimori; Takeji Nishikawa; Chester V Oddis; Yasuo Ikeda
Journal:  Arthritis Rheum       Date:  2005-05

Review 9.  A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.

Authors:  Pedram Gerami; Jennifer M Schope; Lauren McDonald; Hobart W Walling; Richard D Sontheimer
Journal:  J Am Acad Dermatol       Date:  2006-01-23       Impact factor: 11.527

10.  Skin ulcer is a predictive and prognostic factor of acute or subacute interstitial lung disease in dermatomyositis.

Authors:  Kazuyoshi Ishigaki; Junko Maruyama; Noboru Hagino; Atsuko Murota; Yasunobu Takizawa; Ran Nakashima; Tsuneyo Mimori; Keigo Setoguchi
Journal:  Rheumatol Int       Date:  2013-04-04       Impact factor: 2.631

View more
  18 in total

1.  Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.

Authors:  Lili Jiang; Youlian Wang; Qinglin Peng; Xiaoming Shu; Guochun Wang; Xiaomu Wu
Journal:  Clin Rheumatol       Date:  2019-02-09       Impact factor: 2.980

Review 2.  Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.

Authors:  Wanlong Wu; Li Guo; Yakai Fu; Kaiwen Wang; Danting Zhang; Wenwen Xu; Zhiwei Chen; Shuang Ye
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-06       Impact factor: 8.667

3.  [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].

Authors:  Y Z Gan; Y H Li; L H Zhang; L Ma; W W He; Y B Jin; Y An; Z G Li; H Ye
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

4.  Utility of Coagulation Markers for the Prediction of Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis.

Authors:  Tomoya Sagawa; Takashi Kida; Tohru Inaba; Isao Yokota; Risa Sagawa; Akiko Kasahara; Shunya Kaneshita; Takuya Inoue; Hidetake Nagahara; Kazuki Fujioka; Makoto Wada; Masataka Kohno; Yutaka Kawahito
Journal:  Lung       Date:  2019-06-25       Impact factor: 2.584

5.  A New Predictive Model for the Prognosis of MDA5+ DM-ILD.

Authors:  Qian Niu; Li-Qin Zhao; Wan-Li Ma; Liang Xiong; Xiao-Rong Wang; Xin-Liang He; Fan Yu
Journal:  Front Med (Lausanne)       Date:  2022-06-15

6.  Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain.

Authors:  Laura Nuño-Nuño; Beatriz Esther Joven; Patricia E Carreira; Valentina Maldonado-Romero; Carmen Larena-Grijalba; Irene Llorente Cubas; Eva Gloria Tomero; María Carmen Barbadillo-Mateos; Paloma García De la Peña Lefebvre; Lucía Ruiz-Gutiérrez; Juan Carlos López-Robledillo; Henry Moruno-Cruz; Ana Pérez; Tatiana Cobo-Ibáñez; Raquel Almodóvar González; Leticia Lojo; María Jesús García De Yébenes; Francisco Javier López-Longo
Journal:  Rheumatol Int       Date:  2017-09-02       Impact factor: 2.631

Review 7.  Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis.

Authors:  Li Zhang; Guoqin Wu; Di Gao; Guijian Liu; Lin Pan; Liyan Ni; Zheng Li; Qiang Wang
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

8.  Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis.

Authors:  Liubing Li; Qian Wang; Funing Yang; Chanyuan Wu; Si Chen; Xiaoting Wen; Chenxi Liu; Yongzhe Li
Journal:  Oncotarget       Date:  2017-04-18

9.  Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis.

Authors:  Mengmeng Zhou; Yan Ye; Ninghui Yan; Xinyue Lian; Chunde Bao; Qiang Guo
Journal:  Clin Rheumatol       Date:  2020-01-15       Impact factor: 2.980

10.  Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease.

Authors:  Liubing Li; Qian Wang; Xiaoting Wen; Chenxi Liu; Chanyuan Wu; Funing Yang; Xiaofeng Zeng; Yongzhe Li
Journal:  Oncotarget       Date:  2017-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.